Funder: American Heart Association
Due Dates: January 19, 2026 (Letter of Intent, required) | March 23, 2026 (Full application, by invitation)
Funding Amounts: Up to $300,000 per award (including 10% indirect costs) over 2 years; up to 5 awards; AWS credits up to $30,000 for data analysis may be available.
Summary: Supports multidisciplinary, data-driven research on the effects of GLP-1/GIP medications in reducing the burden of cardiovascular kidney metabolic (CKM) disease.
Key Information: Letter of Intent required; full application by invitation only via ProposalCentral.